Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Bevacizumab + Chemotherapy in ES-SCLC
NCT07083375Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Countries
- 1
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Drugs
- QL1706
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in small cell lung cancer (SCLC). Primary endpoint: Progression-Free Survival at 2 years. Planned start Aug 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Combined Treatment Group
QL1706 + Bevacizumab + Platinum-based Chemotherapy
03
Who it enrols
Patients with histologically or cytologically confirmed, treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), ECOG 0-1, and adequate organ function.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Objective Response Rate
Duration of Response
Disease Control Rate
Incidence of Adverse Events
Beyond the preview
Go deeper on NCT07083375.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083375.